# A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

> **NCT05511363** · PHASE3 · RECRUITING · sponsor: **Karuna Therapeutics, Inc., a Bristol Myers Squibb company** · enrollment: 410 (estimated)

## Conditions studied

- Psychosis Associated With Alzheimer's Disease

## Interventions

- **DRUG:** KarXT
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05511363
- **Lead sponsor:** Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-23
- **Primary completion:** 2026-10-05
- **Final completion:** 2026-10-05
- **Target enrollment:** 410 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05511363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05511363, "A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05511363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*